Market Overview:
The global necrotizing fasciitis drug market is expected to grow at a CAGR of XX% during the forecast period from 2018 to 2030. The growth in this market can be attributed to the increasing incidence of necrotizing fasciitis, rising awareness about the disease, and technological advancements in the field of necrotizing fasciitis drugs. The global necrotizing fasciitis drug market is segmented on the basis of type, application, and region. On the basis of type, it is segmented into aminoglycoside antibiotics, metronidazole antibiotics, clindamycin antibiotics, fluoroconazoles antifungals agents (itraconazole), and other drugs. On the basis of application it is segmented into hospital pharmacies; online pharmacies; retail pharmacies; and others (including research institutes). Region wise it covers North America; Latin America; Europe ; Asia Pacific ; Middle East & Africa .
Product Definition:
Necrotizing Fasciitis Drug is a drug that is used to treat necrotizing fasciitis, a rare and life-threatening bacterial infection that affects the tissue beneath the skin. Necrotizing fasciitis can cause extensive damage to the muscles, nerves, and organs. The drug works by killing the bacteria that cause necrotizing fasciitis.
Aminoglycoside:
Aminoglycoside is a type of antibiotic that inhibits the action of bacterial enzymes needed to make proteins. Some aminoglycosides are used to treat infections, such as meningitis and septicemia; others are used in veterinary medicine. The most commonly used antibiotics in medical practice include neomycin, streptomycin, and amikacin; however, many patients develop resistance against these drugs due to frequent usage or overuse.
Metronidazole:
Metronidazole is an antibiotic drug and it's used in the treatment of bacterial infections. It works by killing the bacteria that causes infection. The most common way metronidazole is used is to treat skin infections, such as athlete's foot, ringworm, jock itch, and other fungal or parasitic diseases of the skin. However; it can also be used for treating bacterial pneumonia (e.g.
Application Insights:
Based on the application, the global necrotizing fasciitis drug market is segmented into hospital pharmacies, online pharmacies and retail pharmacies. Hospital pharmacies held a larger share in 2017 as compared to other two segments due to high usage of antimicrobial drugs for treatment of NfD. In addition, presence of key players with extensive distribution channels and brand name in most countries including India, China and Brazil further propels hospital pharmacy segment growth.
Online pharmacy is expected to grow at fastest rate during forecast period owing to increasing use of internet for purchasing medicines instead of visiting local stores or hospitals due to convenience factor. Moreover, growing penetration rates for e-prescription system across the globe will boost online pharmaceutical sales which will eventually propel demand from necrotizing fasciitis drug market over the next few years.
Regional Analysis:
North America dominated the global market in 2017. The presence of key players, favorable reimbursement policies, and increasing healthcare expenditure are some of the factors responsible for its growth. According to a study published in Clinical Infectious Diseases Journal (2016), there was an increase in the incidence of non-Hodgkin lymphoma between 1999 and 2011 among patients aged 15 to 44 years old from 3.4 cases per 100,000 person every year to 4.6 cases per 100,000 person every year during 2011-2013; however, no significant change was observed after 2013 which could be due to changes in reporting guidelines or inadequate follow up time (41).
Growth Factors:
- Increasing incidence of necrotizing fasciitis
- Growing awareness about the disease and its treatment options
- Rising demand for novel necrotizing fasciitis drugs
- Technological advancements in drug development and delivery methods
- increasing funding for necrotizing fasciitis research
Scope Of The Report
Report Attributes
Report Details
Report Title
Necrotizing Fasciitis Drug Market Research Report
By Type
Aminoglycoside, Metronidazole, Clindamycin, Fluoroconazoles, Others, Necrotizing Fasciitis Dru
By Application
Hospital Pharmacies, Online Pharnacies, Retail Pharmacies
By Companies
GlaxoSmithKline, Pfizer, Bristol-Myers Squibb, Merck, Abbott, Teva, WOCKHARDT, Atox Bio, Basilea Pharmaceutica, MELINTA THERAPEUTICS, Necrotizing Fasciitis Dru
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
235
Number of Tables & Figures
165
Customization Available
Yes, the report can be customized as per your need.
Global Necrotizing Fasciitis Drug Market Report Segments:
The global Necrotizing Fasciitis Drug market is segmented on the basis of:
Types
Aminoglycoside, Metronidazole, Clindamycin, Fluoroconazoles, Others, Necrotizing Fasciitis Dru
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Hospital Pharmacies, Online Pharnacies, Retail Pharmacies
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- GlaxoSmithKline
- Pfizer
- Bristol-Myers Squibb
- Merck
- Abbott
- Teva
- WOCKHARDT
- Atox Bio
- Basilea Pharmaceutica
- MELINTA THERAPEUTICS
- Necrotizing Fasciitis Dru
Highlights of The Necrotizing Fasciitis Drug Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Aminoglycoside
- Metronidazole
- Clindamycin
- Fluoroconazoles
- Others
- Necrotizing Fasciitis Dru
- By Application:
- Hospital Pharmacies
- Online Pharnacies
- Retail Pharmacies
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Necrotizing Fasciitis Drug Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Necrotizing Fasciitis Drug is a medication used to treat necrotizing fasciitis, a serious infection of the fascia (the tough layer of tissue that covers the muscle and bones in the body). Necrotizing fasciitis can lead to severe pain, swelling, and bleeding. The drug may also cause fever and chills.
Some of the major players in the necrotizing fasciitis drug market are GlaxoSmithKline, Pfizer, Bristol-Myers Squibb, Merck, Abbott, Teva, WOCKHARDT, Atox Bio, Basilea Pharmaceutica, MELINTA THERAPEUTICS, Necrotizing Fasciitis Dru.
1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. Necrotizing Fasciitis Drug Market Overview
4.1. Introduction
4.1.1. Market Taxonomy
4.1.2. Market Definition
4.2. Macro-Economic Factors
4.2.1. Industry Outlook
4.3. Necrotizing Fasciitis Drug Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Opportunity
4.3.4. Market Trends
4.4. Necrotizing Fasciitis Drug Market - Supply Chain
4.5. Global Necrotizing Fasciitis Drug Market Forecast
4.5.1. Necrotizing Fasciitis Drug Market Size (US$ Mn) and Y-o-Y Growth
4.5.2. Necrotizing Fasciitis Drug Market Size (000 Units) and Y-o-Y Growth
4.5.3. Necrotizing Fasciitis Drug Market Absolute $ Opportunity
5. Global Necrotizing Fasciitis Drug Market Analysis and Forecast by Type
5.1. Market Trends
5.2. Introduction
5.2.1. Basis Point Share (BPS) Analysis by Type
5.2.2. Y-o-Y Growth Projections by Type
5.3. Necrotizing Fasciitis Drug Market Size and Volume Forecast by Type
5.3.1. Aminoglycoside
5.3.2. Metronidazole
5.3.3. Clindamycin
5.3.4. Fluoroconazoles
5.3.5. Others
5.3.6. Necrotizing Fasciitis Dru
5.4. Absolute $ Opportunity Assessment by Type
5.5. Market Attractiveness/Growth Potential Analysis by Type
6. Global Necrotizing Fasciitis Drug Market Analysis and Forecast by Application
6.1. Market Trends
6.2. Introduction
6.2.1. Basis Point Share (BPS) Analysis by Application
6.2.2. Y-o-Y Growth Projections by Application
6.3. Necrotizing Fasciitis Drug Market Size and Volume Forecast by Application
6.3.1. Hospital Pharmacies
6.3.2. Online Pharnacies
6.3.3. Retail Pharmacies
6.4. Absolute $ Opportunity Assessment by Application
6.5. Market Attractiveness/Growth Potential Analysis by Application
7. Global Necrotizing Fasciitis Drug Market Analysis and Forecast by Sales Channel
7.1. Market Trends
7.2. Introduction
7.2.1. Basis Point Share (BPS) Analysis by Sales Channel
7.2.2. Y-o-Y Growth Projections by Sales Channel
7.3. Necrotizing Fasciitis Drug Market Size and Volume Forecast by Sales Channel
7.3.1. Manufacturer/Distributor/Service Provider
7.3.2. Aftermarket
7.4. Absolute $ Opportunity Assessment by Sales Channel
7.5. Market Attractiveness/Growth Potential Analysis by Sales Channel
8. Global Necrotizing Fasciitis Drug Market Analysis and Forecast by Region
8.1. Market Trends
8.2. Introduction
8.2.1. Basis Point Share (BPS) Analysis by Region
8.2.2. Y-o-Y Growth Projections by Region
8.3. Necrotizing Fasciitis Drug Market Size and Volume Forecast by Region
8.3.1. North America
8.3.2. Latin America
8.3.3. Europe
8.3.4. Asia Pacific
8.3.5. Middle East and Africa (MEA)
8.4. Absolute $ Opportunity Assessment by Region
8.5. Market Attractiveness/Growth Potential Analysis by Region
8.6. Global Necrotizing Fasciitis Drug Demand Share Forecast, 2019-2026
9. North America Necrotizing Fasciitis Drug Market Analysis and Forecast
9.1. Introduction
9.1.1. Basis Point Share (BPS) Analysis by Country
9.1.2. Y-o-Y Growth Projections by Country
9.2. North America Necrotizing Fasciitis Drug Market Size and Volume Forecast by Country
9.2.1. U.S.
9.2.2. Canada
9.3. Absolute $ Opportunity Assessment by Country
9.4. North America Necrotizing Fasciitis Drug Market Size and Volume Forecast by Application
9.4.1. Hospital Pharmacies
9.4.2. Online Pharnacies
9.4.3. Retail Pharmacies
9.5. Basis Point Share (BPS) Analysis by Application
9.6. Y-o-Y Growth Projections by Application
9.7. North America Necrotizing Fasciitis Drug Market Size and Volume Forecast by Type
9.7.1. Aminoglycoside
9.7.2. Metronidazole
9.7.3. Clindamycin
9.7.4. Fluoroconazoles
9.7.5. Others
9.7.6. Necrotizing Fasciitis Dru
9.8. Basis Point Share (BPS) Analysis by Type
9.9. Y-o-Y Growth Projections by Type
9.10. Market Attractiveness/Growth Potential Analysis
9.10.1. By Country
9.10.2. By Product Type
9.10.3. By Application
9.10.4. By Sales Channel
9.11. North America Necrotizing Fasciitis Drug Demand Share Forecast, 2019-2026
10. Latin America Necrotizing Fasciitis Drug Market Analysis and Forecast
10.1. Introduction
10.1.1. Basis Point Share (BPS) Analysis by Country
10.1.2. Y-o-Y Growth Projections by Country
10.1.3. Latin America Average Pricing Analysis
10.2. Latin America Necrotizing Fasciitis Drug Market Size and Volume Forecast by Country
10.2.1. Brazil
10.2.2. Mexico
10.2.3. Rest of Latin America
10.3. Absolute $ Opportunity Assessment by Country
10.4. Latin America Necrotizing Fasciitis Drug Market Size and Volume Forecast by Application
10.4.1. Hospital Pharmacies
10.4.2. Online Pharnacies
10.4.3. Retail Pharmacies
10.5. Basis Point Share (BPS) Analysis by Application
10.6. Y-o-Y Growth Projections by Application
10.7. Latin America Necrotizing Fasciitis Drug Market Size and Volume Forecast by Type
10.7.1. Aminoglycoside
10.7.2. Metronidazole
10.7.3. Clindamycin
10.7.4. Fluoroconazoles
10.7.5. Others
10.7.6. Necrotizing Fasciitis Dru
10.8. Basis Point Share (BPS) Analysis by Type
10.9. Y-o-Y Growth Projections by Type
10.10. Market Attractiveness/Growth Potential Analysis
10.10.1. By Country
10.10.2. By Product Type
10.10.3. By Application
10.10.4. By Sales Channel
10.11. Latin America Necrotizing Fasciitis Drug Demand Share Forecast, 2019-2026
11. Europe Necrotizing Fasciitis Drug Market Analysis and Forecast
11.1. Introduction
11.1.1. Basis Point Share (BPS) Analysis by Country
11.1.2. Y-o-Y Growth Projections by Country
11.1.3. Europe Average Pricing Analysis
11.2. Europe Necrotizing Fasciitis Drug Market Size and Volume Forecast by Country
11.2.1. Germany
11.2.2. France
11.2.3. Italy
11.2.4. U.K.
11.2.5. Spain
11.2.6. Russia
11.2.7. Rest of Europe
11.3. Absolute $ Opportunity Assessment by Country
11.4. Europe Necrotizing Fasciitis Drug Market Size and Volume Forecast by Application
11.4.1. Hospital Pharmacies
11.4.2. Online Pharnacies
11.4.3. Retail Pharmacies
11.5. Basis Point Share (BPS) Analysis by Application
11.6. Y-o-Y Growth Projections by Application
11.7. Europe Necrotizing Fasciitis Drug Market Size and Volume Forecast by Type
11.7.1. Aminoglycoside
11.7.2. Metronidazole
11.7.3. Clindamycin
11.7.4. Fluoroonazoles
11.7.5. Others
11.7.6. Necrotizing Fasciitis Dru
11.8. Basis Point Share (BPS) Analysis by Type
11.9. Y-o-Y Growth Projections by Type
11.10. Market Attractiveness/Growth Potential Analysis
11.10.1. By Country
11.10.2. By Product Type
11.10.3. By Application
11.10.4. By Sales Channel
11.11. Europe Necrotizing Fasciitis Drug Demand Share, 2019-2026
12. Asia Pacific Necrotizing Fasciitis Drug Market Analysis and Forecast
12.1. Introduction
12.1.1. Basis Point Share (BPS) Analysis by Country
12.1.2. Y-o-Y Growth Projections by Country
12.1.3. Asia Pacific Average Pricing Analysis
12.2. Asia Pacific Necrotizing Fasciitis Drug Market Size and Volume Forecast by Country
12.2.1. China
12.2.2. Japan
12.2.3. South Korea
12.2.4. India
12.2.5. Australia
12.2.6. Rest of Asia Pacific (APAC)
12.3. Absolute $ Opportunity Assessment by Country
12.4. Asia Pacific Necrotizing Fasciitis Drug Market Size and Volume Forecast by Application
12.4.1. Hospital Pharmacies
12.4.2. Online Pharnacies
12.4.3. Retail Pharmacies
12.5. Basis Point Share (BPS) Analysis by Application
12.6. Y-o-Y Growth Projections by Application
12.7. Asia Pacific Necrotizing Fasciitis Drug Market Size and Volume Forecast by Type
12.7.1. Aminoglycoside
12.7.2. Metronidazole
12.7.3. Clindamycin
12.7.4. Fluoroconazoles
12.7.5. Others
12.7.6. Necrotizing Fasciitis Dru
12.8. Basis Point Share (BPS) Analysis by Type
12.9. Y-o-Y Growth Projections by Type
12.10. Market Attractiveness/Growth Potential Analysis
12.10.1. By Country
12.10.2. By Product Type
12.10.3. By Application
12.10.4. By Sales Channel
12.11. Asia Pacific Necrotizing Fasciitis Drug Demand Share, 2019-2026
13. Middle East & Africa Necrotizing Fasciitis Drug Market Analysis and Forecast
13.1. Introduction
13.1.1. Basis Point Share (BPS) Analysis by Country
13.1.2. Y-o-Y Growth Projections by Country
13.1.3. Asia Pacific Average Pricing Analysis
13.2. Middle East & Africa Necrotizing Fasciitis Drug Market Size and Volume Forecast by Country
13.2.1. Saudi Arabia
13.2.2. South Africa
13.2.3. UAE
13.2.4. Rest of Middle East & Africa (MEA)
13.3. Absolute $ Opportunity Assessment by Country
13.4. Middle East & Africa Necrotizing Fasciitis Drug Market Size and Volume Forecast by Application
13.4.1. Hospital Pharmacies
13.4.2. Online Pharnacies
13.4.3. Retail Pharmacies
13.5. Basis Point Share (BPS) Analysis by Application
13.6. Y-o-Y Growth Projections by Application
13.7. Middle East & Africa Necrotizing Fasciitis Drug Market Size and Volume Forecast by Type
13.7.1. Aminoglycoside
13.7.2. Metronidazole
13.7.3. Clindamycin
13.7.4. Fluoroconazoles
13.7.5. Others
13.7.6. Necrotizing Fasciitis Dru
13.8. Basis Point Share (BPS) Analysis by Type
13.9. Y-o-Y Growth Projections by Type
13.10. Market Attractiveness/Growth Potential Analysis
13.10.1. By Country
13.10.2. By Product Type
13.10.3. By Application
13.10.4. By Sales Channel
13.11. Middle East & Africa Necrotizing Fasciitis Drug Demand Share, 2019-2026
14. Competition Landscape
14.1. Global Necrotizing Fasciitis Drug Market: Market Share Analysis
14.2. Necrotizing Fasciitis Drug Distributors and Customers
14.3. Necrotizing Fasciitis Drug Market: Competitive Dashboard
14.4. Company Profiles (Details Overview, Financials, Developments, Strategy)
14.4.1. GlaxoSmithKline
14.4.1.1. Overview
14.4.1.2. Financials
14.4.1.3. Developments
14.4.1.4. Strategic Outlook
14.4.2. Pfizer
14.4.2.1. Overview
14.4.2.2. Financials
14.4.2.3. Developments
14.4.2.4. Strategic Outlook
14.4.3. Bristol-Myers Squibb
14.4.3.1. Overview
14.4.3.2. Financials
14.4.3.3. Developments
14.4.3.4. Strategic Outlook
14.4.4. Merck
14.4.4.1. Overview
14.4.4.2. Financials
14.4.4.3. Developments
14.4.4.4. Strategic Outlook
14.4.5. Abbott
14.4.5.1. Overview
14.4.5.2. Financials
14.4.5.3. Developments
14.4.5.4. Strategic Outlook
14.4.6. Teva
14.4.6.1. Overview
14.4.6.2. Financials
14.4.6.3. Developments
14.4.6.4. Strategic Outlook
14.4.7. WOCKHARDT
14.4.7.1. Overview
14.4.7.2. Financials
14.4.7.3. Developments
14.4.7.4. Strategic Outlook
14.4.8. Atox Bio
14.4.8.1. Overview
14.4.8.2. Financials
14.4.8.3. Developments
14.4.8.4. Strategic Outlook
14.4.9. Basilea Pharmaceutica
14.4.9.1. Overview
14.4.9.2. Financials
14.4.9.3. Developments
14.4.9.4. Strategic Outlook
14.4.10. MELINTA THERAPEUTICS
14.4.10.1. Overview
14.4.10.2. Financials
14.4.10.3. Developments
14.4.10.4. Strategic Outlook
14.4.11. Necrotizing Fasciitis Dru
14.4.11.1. Overview
14.4.11.2. Financials
14.4.11.3. Developments
14.4.11.4. Strategic Outlook
14.4.12. COMPANY 12
14.4.12.1. Overview
14.4.12.2. Financials
14.4.12.3. Developments
14.4.12.4. Strategic Outlook
14.4.13. COMPANY 13
14.4.13.1. Overview
14.4.13.2. Financials
14.4.13.3. Developments
14.4.13.4. Strategic Outlook
14.4.14. COMPANY 14
14.4.14.1. Overview
14.4.14.2. Financials
14.4.14.3. Developments
14.4.14.4. Strategic Outlook
14.4.15. COMPANY 15
14.4.15.1. Overview
14.4.15.2. Financials
14.4.15.3. Developments
14.4.15.4. Strategic Outlook
14.4.16. COMPANY 16
14.4.16.1. Overview
14.4.16.2. Financials
14.4.16.3. Developments
14.4.16.4. Strategic Outlook
14.4.17. COMPANY 17
14.4.17.1. Overview
14.4.17.2. Financials
14.4.17.3. Developments
14.4.17.4. Strategic Outlook
14.4.18. COMPANY 18
14.4.18.1. Overview
14.4.18.2. Financials
14.4.18.3. Developments
14.4.18.4. Strategic Outlook
14.4.19. COMPANY 19
14.4.19.1. Overview
14.4.19.2. Financials
14.4.19.3. Developments
14.4.19.4. Strategic Outlook
14.4.20. COMPANY 20
14.4.20.1. Overview
14.4.20.2. Financials
14.4.20.3. Developments
14.4.20.4. Strategic Outlook
